Taylor R W, Jackson S, Pourfarzam M, Bartlett K, Turnbull D M
Division of Clinical Neuroscience, Medical School, University of Newcastle upon Tyne, UK.
J Inherit Metab Dis. 1992;15(5):727-32. doi: 10.1007/BF01800014.
The measurement of acyl-CoA dehydrogenase activity is an essential part of the investigation of patients with suspected defects of fatty acid oxidation, and recently the organometallic oxidant ferricenium hexafluorophosphate has been introduced as an electron acceptor for these assays. However, we show that when medium-chain acyl-CoA dehydrogenase activity was measured in cultured skin fibroblasts and platelets from patients with proven defects of this enzyme, there was considerable residual enzyme activity when this electron acceptor was used. The ferricenium assay is not as specific as the anaerobic ETF-linked assay in the biochemical diagnosis of medium-chain acyl-CoA dehydrogenase deficiency in fibroblasts, and therefore is of limited clinical applicability in its present form.
酰基辅酶A脱氢酶活性的测定是对疑似脂肪酸氧化缺陷患者进行调查的重要组成部分,最近,有机金属氧化剂六氟磷酸铁鎓已被用作这些检测的电子受体。然而,我们发现,当使用这种电子受体来测定患有该酶已证实缺陷的患者的培养皮肤成纤维细胞和血小板中的中链酰基辅酶A脱氢酶活性时,仍存在相当大的残余酶活性。在成纤维细胞中链酰基辅酶A脱氢酶缺乏症的生化诊断中,铁鎓检测不如厌氧ETF连接检测特异,因此其目前形式的临床适用性有限。